China’s State Council Order No. 818, the Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies, took effect on 1 May 2026. The regulation establishes a dual-track framework for biomedical innovation, with the existing NMPA medical-device and drug-registration route running parallel to a new National Health Commission pathway under which qualified hospitals can charge for clinical application of approved technologies. Brain-computer interfaces are explicitly named as one of four covered categories, alongside personalised cell therapies, gene editing applications, and xenotransplantation. The regulation does not replace NMPA review for BCI products classified as medical devices. It creates a second route for technologies acting at the cellular or molecular level on the human body that have not yet been applied clinically within China.
Order 818 lands twelve days after the National Healthcare Security Administration issued guided pricing for invasive BCI procedures (23 April) and seven weeks after Neuracle Medical Technology cleared NMPA approval for an invasive BCI under the standard medical-device pathway (13 March). The Industrial Builder posture the Dargentic Neurotechnology Report (Spring 2026) maps for China on Page 18 is now operating across three layers simultaneously: the regulatory pathway (Order 818 alongside NMPA), the reimbursement framework (NHSA pricing), and the first commercial validation (Neuracle NEO).
What the dual-track mechanism does
Article 3 of Order 818 defines “biomedical new technologies” as medical professional methods and measures that apply biological principles, act at the cellular or molecular level on the human body, and have not yet been applied clinically within China. Article 6 places nationwide supervision with the National Health Commission. Article 10 requires the clinical research sponsor to be a legal entity established within China. Article 20 prohibits sponsors from charging research subjects fees during the clinical research phase, preserving the non-commercial integrity of investigational trials. Articles 25 and 26 set the translation mechanism: once safety and preliminary efficacy are demonstrated, the sponsoring institution can apply to translate the technology into clinical application at qualified hospitals. Article 34 unlocks hospital fee-charging once the translation application is approved.
Article 55 explicitly preserves the NMPA pathway. Clinical trials conducted to develop drugs or medical devices continue under the Drug Administration Law and the Regulations on Supervision and Administration of Medical Devices. The NHC and NMPA will jointly issue Boundary Delineation Guidelines to clarify which technologies fall under which pathway. Those guidelines have not yet been published. The boundary determination will be the deciding variable for any sponsor evaluating which track to pursue.
Where BCI fits inside the framework
Neuracle Medical Technology cleared its invasive BCI under the NMPA medical-device track on 13 March 2026, before Order 818 took effect. The Neuracle NEO is the in-market reference point for the China BCI cohort and remains under NMPA jurisdiction. Order 818 is the option for future BCI entrants whose products are not strictly device-classified and may qualify under the molecular-level methods-and-measures definition. The boundary question for BCI is whether an invasive cortical electrode array reading neural signals counts as a medical device or a biomedical new technology. Until the Boundary Delineation Guidelines are issued, Chinese BCI sponsors face a strategic choice rather than a deterministic pathway.
NeuroXess, BrainCo, NeuCyber, and StairMed are the most prominent Chinese BCI companies that could benefit from Order 818 in 2026. None has publicly announced intent to use the route. The first formal application will be the marker for how the NHC interprets the boundary in practice and which BCI architectures the agency considers translatable under the new track.
What the regulation closes off to foreign companies
China’s 2024 Foreign Investment Negative List Article 17 prohibits foreign investment in human stem cells, gene diagnosis, and gene treatment technologies. The State Council’s September 2024 pilot relaxation in the Beijing, Shanghai, Guangdong, and Hainan free trade zones permits foreign-invested enterprises to engage in cell and gene therapy development, but only for activities intended for NMPA product registration and production. Whether foreign-invested enterprises can use the Order 818 technology translation pathway is, in Morgan Lewis’s reading, a grey area and a substantial compliance risk pending further guidance.
Domestic Chinese BCI players gain a second commercial pathway under Order 818 with hospital-fee revenue capture and a faster route to in-China commercialisation. Foreign players remain bound to the NMPA medical-device route, with the FTZ pilot still untested for BCI products and the Order 818 pathway effectively closed. The asymmetry widens rather than narrows. Multinational pharma and medtech players evaluating Chinese BCI assets for licensing or acquisition now face an additional layer of structural complexity. Human genetic resources compliance, cross-border data transfer rules, and technology export controls all interact with how an asset has been commercialised in China and on which track.
What to watch
The Boundary Delineation Guidelines from the NHC and NMPA will be the operational test for how Order 818 actually applies to BCI. The first Chinese BCI sponsor to publicly elect the Order 818 pathway will set the precedent for whether the regulation functions as a real second lane for the cohort or remains a primarily cell-and-gene-therapy framework that BCI happens to be eligible for. The qualifying-hospital criteria for translation approval will determine how concentrated commercial deployment becomes, whether a small number of approved tertiary centres in Beijing, Shanghai, and Guangzhou, or broader provincial distribution.
Order 818 is the regulatory pathway leg of an Industrial Builder stack now visibly operating in real time. The next observable signals are the Boundary Delineation Guidelines, the first BCI translation application, and the next provincial NHSA pricing decisions. The China cohort’s commercial position relative to the Western cohort hardens further with each layer that goes live.
Sources: Morgan Lewis LawFlash on Order 818, 6 May 2026. Caixin Global, 24 April 2026. Han Kun Law analysis on Order 818. Pacific Bridge Medical brief.